RTTNews | Sep 20, 2021 09:58AM EDT

09:58 Monday, September 20, 2021 (RTTNews.com) - AbbVie (ABBV) has submitted an application to the FDA seeking approval for risankizumab-rzaa or SKYRIZI, for the treatment of patients 16 years and older with moderate to severe Crohn's disease. The submission is supported by data from three phase 3 studies - ADVANCE, MOTIVATE and FORTIFY.

Crohn's disease is a chronic disease that manifests as inflammation within the gastrointestinal tract, causing persistent diarrhea, abdominal pain, and rectal bleeding.

SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

Read the original article on RTTNews ( https://www.rttnews.com/3226894/abbvie-seeks-approval-for-skyrizi-based-on-data-from-three-phase-3-studies.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved